Dashboard
Manage Tickers

ACLXArcellx, Inc.

Nasdaq arcellx.com


$ 52.21 $ 0.71 (1.38 %)    

Friday, 26-Apr-2024 13:06:24 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 432.19 $ 4.21 (0.98 %)
DIA $ 382.87 $ 2.25 (0.59 %)
SPY $ 509.56 $ 1.37 (0.27 %)
TLT $ 88.24 $ -0.03 (-0.03 %)
GLD $ 216.26 $ -1.02 (-0.47 %)
$ 51.38
$ 51.50
$ 0.00 x 0
$ 52.18 x 100
$ 51.37 - $ 52.23
$ 30.74 - $ 75.10
631,751
na
2.47B
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

peering-into-arcellxs-recent-short-interest
Peering Into Arcellx's Recent Short Interest
04/15/2024 15:00:31

needham-reiterates-buy-on-arcellx-maintains-81-price-target
Needham Reiterates Buy on Arcellx, Maintai...
04/11/2024 10:13:25

Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $81 price target.

needham-maintains-buy-on-arcellx-raises-price-target-to-81
Needham Maintains Buy on Arcellx, Raises P...
03/18/2024 11:12:50

Needham analyst Gil Blum maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $72 to $81.

stifel-reiterates-buy-on-arcellx-maintains-82-price-target
Stifel Reiterates Buy on Arcellx, Maintain...
03/14/2024 16:40:39

Stifel analyst Benjamin Burnett reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $82 price target.

arcellxs-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson--johnsons-multiple-myeloma-cell-therapies-morgan-stanley
Arcellx's Lead Asset Can Potentially Outpe...
03/07/2024 19:52:19

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differenti...

morgan-stanley-initiates-coverage-on-arcellx-with-overweight-rating-announces-price-target-of-81
Morgan Stanley Initiates Coverage On Arcel...
03/07/2024 08:56:28

Morgan Stanley analyst Judah Frommer initiates coverage on Arcellx (NASDAQ:ACLX) with a Overweight rating and announces Pric...

truist-securities-maintains-buy-on-arcellx-raises-price-target-to-87
Truist Securities Maintains Buy on Arcellx...
03/05/2024 15:17:33

Truist Securities analyst Asthika Goonewardene maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $...

hc-wainwright--co-maintains-buy-on-arcellx-raises-price-target-to-82
HC Wainwright & Co. Maintains Buy on Arcel...
02/29/2024 20:28:51

HC Wainwright & Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $60...

on-wednesday-february-28-2024-arcellx-reported-q4-eps-042-up-from-076-yoy-sales-6315m
On Wednesday February 28, 2024, Arcellx Re...
02/29/2024 20:28:09

Arcellx (NASDAQ:ACLX) reported quarterly earnings of $0.42 per share. This is a 155.26 percent increase over losses of $(0.76) ...

canaccord-genuity-maintains-buy-on-arcellx-raises-price-target-to-85
Canaccord Genuity Maintains Buy on Arcellx...
02/29/2024 14:56:02

Canaccord Genuity analyst John Newman maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $66 to $85.

barclays-maintains-overweight-on-arcellx-raises-price-target-to-73
Barclays Maintains Overweight on Arcellx, ...
02/29/2024 14:05:33

Barclays analyst Carter Gould maintains Arcellx (NASDAQ:ACLX) with a Overweight and raises the price target from $62 to $73.

arcellx-analysts-boost-their-forecasts-after-q4-results
Arcellx Analysts Boost Their Forecasts Aft...
02/29/2024 13:03:24

Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday.

needham-maintains-buy-on-arcellx-raises-price-target-to-72
Needham Maintains Buy on Arcellx, Raises P...
02/29/2024 12:51:14

Needham analyst Gil Blum maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $71 to $72.

baird-maintains-outperform-on-arcellx-raises-price-target-to-77
Baird Maintains Outperform on Arcellx, Rai...
02/29/2024 12:14:19

Baird analyst Jack Allen maintains Arcellx (NASDAQ:ACLX) with a Outperform and raises the price target from $63 to $77.

as-of-december-31-2023-arcellx-had-cash-cash-equivalents-and-marketable-securities-of-7292m-will-fund-its-operations-into-2027
As Of December 31, 2023, Arcellx Had Cash,...
02/28/2024 21:29:34

Fourth Quarter and Full Year 2023 Financial HighlightsCash, cash equivalents, and marketable securities:  As of December 31, 20...

Core News & Articles
Blood Cancer Player Arcellx Finds Place On...
01/04/2024 19:08:32

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & ...

needham-maintains-buy-rating-for-arcellx-heres-what-you-need-to-know
Needham Maintains Buy Rating for Arcellx: ...
01/04/2024 17:00:32

needham-maintains-buy-on-arcellx-raises-price-target-to-71
Needham Maintains Buy on Arcellx, Raises P...
01/04/2024 11:15:59

Needham analyst Gil Blum maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $65 to $71.

scotiabank-initiates-coverage-on-arcellx-with-sector-outperform-rating-announces-price-target-of-66
Scotiabank Initiates Coverage On Arcellx w...
12/19/2023 16:29:32

Scotiabank analyst George Farmer initiates coverage on Arcellx (NASDAQ:ACLX) with a Sector Outperform rating and announces P...

why-johnson-controls-international-shares-are-trading-lower-by-over-6-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Johnson Controls International Shares ...
12/12/2023 18:22:22

Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION